Patents by Inventor Xiaozhang Zheng

Xiaozhang Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amido spirocyclic amide and sulfonamide derivatives
    Patent number: 11485745
    Abstract: Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: November 1, 2022
    Assignees: Valo Health, Inc., Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Peter Dragovich, Xiongcai Liu, Snahel Patel, Po-Wai Yuen, Mark Zak, Guiling Zhao, Yamin Zhang, Xiaozhang Zheng
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20220340570
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 17, 2020
    Publication date: October 27, 2022
    Inventors: Matthew M. WEISS, Xiaozhang ZHENG, Xiao ZHU
  • Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
    Patent number: 11479564
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: October 25, 2022
    Assignee: Valo Health, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Judith D. Kuntz, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20220324854
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 14, 2022
    Publication date: October 13, 2022
    Inventors: Nello MAINOLFI, Nan Ji, Arthur F. Kluge, Matthew M. Weiss, Yi Zhang, Xiaozhang Zheng
  • INHIBITING FATTY ACID SYNTHASE (FASN)
    Publication number: 20220315565
    Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.
    Type: Application
    Filed: February 10, 2022
    Publication date: October 6, 2022
    Inventors: Matthew W. Martin, Mary-Margaret Zablocki, Scot Mente, Christopher Dinsmore, Zhongguo Wang, Xiaozhang Zheng
  • FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF
    Publication number: 20220281831
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same. The present invention also relates to compounds and methods useful for binding and modulating the activity of cereblon (CRBN), especially for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.
    Type: Application
    Filed: July 15, 2020
    Publication date: September 8, 2022
    Inventors: Nan JI, Michael d. SINTCHAK, Li ZHANG, Xiaozhang ZHENG
  • [6,6] fused bicyclic HDAC8 inhibitors
    Patent number: 11414392
    Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2?, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: August 16, 2022
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Jennifer R. Thomason, Mary-Margaret Zablocki, Bingsong Han, Nicholas Barczak, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., Kenneth W. Bair
  • METHODS USING HDAC11 INHIBITORS
    Publication number: 20220235018
    Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.
    Type: Application
    Filed: April 1, 2022
    Publication date: July 28, 2022
    Inventors: Jennifer Lee, Nicholas Barczak, Jaime A. Escobedo, Chiara Conti, Bingsong Han, David R. Lancia, JR., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Xiaozhang Zheng
  • Compositions for activating pyruvate kinase
    Patent number: 11396513
    Abstract: Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: July 26, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, Jr., Lorna Mitchell, Tatiana Shelekhin
  • 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
    Publication number: 20220204461
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Application
    Filed: March 10, 2022
    Publication date: June 30, 2022
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, JR., David S. Millan, Matthew W. Martin
  • IRAK degraders and uses thereof
    Patent number: 11352350
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: June 7, 2022
    Assignee: KYMERA THERAPEUTICS, INC.
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Kluge, Matthew M. Weiss, Yi Zhang, Xiaozhang Zheng
  • Methods using HDAC11 inhibitors
    Patent number: 11345672
    Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: May 31, 2022
    Assignee: Valo Health, Inc.
    Inventors: Jennifer Lee, Nicholas Barczak, Jaime A. Escobedo, Chiara Conti, Bingsong Han, David R. Lancia, Jr., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Xiaozhang Zheng
  • Inhibiting fatty acid synthase (FASN)
    Patent number: 11299484
    Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: April 12, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Matthew W. Martin, Mary-Margaret Zablocki, Scot Mente, Christopher Dinsmore, Zhongguo Wang, Xiaozhang Zheng
  • 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 11279681
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: March 22, 2022
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin, Kenneth W. Bair
  • Compounds and compositions for the inhibition of NAMPT
    Patent number: 11279687
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An embodiment of the invention is the provision of a compound of Formula IIIA.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 22, 2022
    Assignees: Valo Health, Inc., Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng, Po-Wai Yuen
  • 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 11274085
    Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: March 15, 2022
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin
  • 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 11274084
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: March 15, 2022
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin
  • ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS
    Publication number: 20220073452
    Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
    Type: Application
    Filed: April 23, 2021
    Publication date: March 10, 2022
    Inventors: Kenneth W. Bair, Nicholas Barczak, Bingsong Han, David R. Lancia, JR., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Mary-Margaret Zablocki, Xiaozhang Zheng
  • CRYSTALLINE FORMS OF IRAK DEGRADERS
    Publication number: 20210395273
    Abstract: The present disclosure relates generally to various forms, salts and compositions of compounds useful for the modulation of one or more interleukin-1 receptor-associated kinases (“IRAK”) via ubiquitination and/or degradation and uses of the same in the treatment various diseases.
    Type: Application
    Filed: June 3, 2021
    Publication date: December 23, 2021
    Inventors: Xiaozhang Zheng, Don Corson
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20210323952
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 2, 2019
    Publication date: October 21, 2021
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Kluge, Matthew M. Weiss, Yi Zhang, Xiaozhang Zheng